Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.54 USD
-0.10 (-0.86%)
Updated Jul 26, 2024 01:54 PM ET
After-Market: $11.52 -0.02 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Avalo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 18 | 5 | 7 | 7 |
Cost Of Goods | 1 | 3 | 1 | 0 | -1 |
Gross Profit | 1 | 15 | 4 | 6 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 28 | 52 | 86 | 79 | 23 |
Income After Depreciation & Amortization | -27 | -37 | -82 | -73 | -16 |
Non-Operating Income | -1 | 0 | -2 | 6 | 0 |
Interest Expense | 3 | 4 | 0 | 0 | 0 |
Pretax Income | -32 | -42 | -85 | -67 | -16 |
Income Taxes | 0 | 0 | 0 | -3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -42 | -84 | -64 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 1 | 0 |
Net Income (GAAP) | -32 | -42 | -84 | -64 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -36 | -80 | -71 | -11 |
Depreciation & Amortization (Cash Flow) | 6 | 2 | 2 | 2 | 5 |
Income After Depreciation & Amortization | -27 | -37 | -82 | -73 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.28 | 0.04 | 0.04 | 0.03 | 0.02 |
Diluted EPS Before Non-Recurring Items | -114.00 | -1,054.76 | -2,372.38 | -1,629.22 | -857.49 |
Diluted Net EPS (GAAP) | -114.00 | -1,054.76 | NA | NA | -800.32 |
Fiscal Year end for Avalo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.57 | 0.24 | 0.64 |
Cost Of Goods | NA | -0.08 | -0.22 | 0.25 | 0.71 |
Gross Profit | NA | 0.08 | 0.79 | -0.01 | -0.07 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 32.84 | 8.46 | 3.74 | 7.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -32.76 | -7.67 | -3.75 | -7.16 |
Non-Operating Income | NA | -88.52 | -0.60 | 0.08 | -0.04 |
Interest Expense | NA | 0.00 | -0.08 | 1.55 | 1.00 |
Pretax Income | NA | -121.28 | -8.18 | -5.22 | -8.19 |
Income Taxes | NA | 0.01 | -0.01 | 0.01 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -121.29 | -8.17 | -5.23 | -8.19 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -121.29 | -8.17 | -5.23 | -8.19 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.86 | NA | 0.20 | 0.06 |
Diluted EPS Before Non-Recurring Items | NA | -5.98 | NA | -26.19 | -140.48 |
Diluted Net EPS (GAAP) | NA | -141.00 | 255.05 | -26.19 | -140.48 |